Concomitant use of beta2-agonists and beta-blockers in patients with comorbid acute heart failure and COPD appears to be safe and effective based on observational data and clinical expertise.
Concomitant use of beta2-agonists and beta-blockers appears safe and effective for managing acute heart failure in patients with comorbid COPD.
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) comorbidity poses substantial diagnostic and therapeutic challenges in acute care settings. The specific role of pulmonary comorbidity in the treatment and outcomes of cardiovascular disease patients was not addressed in any short- or long-term prospective study. Both HF and COPD can be interpreted as systemic disorders associated with low-grade inflammation, endothelial dysfunction, vascular remodelling and skeletal muscle atrophy. HF is regularly treated as a broader cardiopulmonary syndrome utilising acute respiratory therapy. Based on observational data and clinical expertise, a management strategy of concurrent HF and COPD in acute settings is suggested. Concomitant use of beta2-agonists and beta-blockers in a comorbid cardiopulmonary condition seems to be safe and effective.
Čelutkienė et al. (Sun,) conducted a review in Acute Heart Failure and Chronic Obstructive Pulmonary Disease. Concomitant use of beta2-agonists and beta-blockers was evaluated. Concomitant use of beta2-agonists and beta-blockers in patients with comorbid acute heart failure and COPD appears to be safe and effective based on observational data and clinical expertise.